- Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer
-
Allahverdiyev A, Tari G, Bagirova M, Abamor ES
- KMID: 2429812
- J Breast Cancer.
- 2018 Dec;21(4):343-353.
- doi: 10.4048/jbc.2018.21.e47
Cancer is the leading cause of death worldwide. In developed as well as developing countries, breast cancer is the most common cancer found among women. Currently, treatment of breast cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- Dendritic cell-based therapeutic cancer vaccines: past, present and future
-
Ahmed MS, Bae YS
- KMID: 1730614
- Clin Exp Vaccine Res.
- 2014 Jul;3(2):113-116.
- doi: 10.7774/cevr.2014.3.2.113
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Distinct features of dendritic cell-based immunotherapy as cancer vaccines
-
Lee C, Lee M, Rhee I
- KMID: 2402534
- Clin Exp Vaccine Res.
- 2018 Jan;7(1):16-23.
- doi: 10.7774/cevr.2018.7.1.16
Dendritic cells (DCs) are the most professional antigen presenting cells that play important roles in connection between innate and adaptive immune responses. Numerous studies revealed that the functions of DCs... -
- CITED
-
- Close
- SHARE
-
- Close
- Cancer Vaccines
-
Son EW, In SW, Pyo S
- KMID: 2150599
- Immune Netw.
- 2005 Jun;5(2):55-67.
- doi: 10.4110/in.2005.5.2.55
Cancer vaccine is an active immunotherapy to stimulate the immune system to mount a response against the tumor specific antigen. Working as a stimulant to the body's own immune system,... -
- CITED
-
- Close
- SHARE
-
- Close
- Immunotherapy for Non-Small Cell Lung Cancer
-
Yoon SH
- KMID: 2320556
- Tuberc Respir Dis.
- 2014 Sep;77(3):111-115.
- doi: 10.4046/trd.2014.77.3.111
Lung cancer is the leading cause of cancer-related mortality worldwide, and more than 80% of cases are of non-small cell lung cancer. Although chemotherapy and molecularly targeted therapy may provide... -
- CITED
-
- Close
- SHARE
-
- Close
- Cervical Cancer and Human Papillomavirus Vaccines
-
Kim S, Kwak JI, Song YM
- KMID: 2294396
- J Korean Acad Fam Med.
- 2008 Nov;29(11):821-830.
The necessary role of genital infection by specific types of human papillomavirus (HPV) in cervical cancer development provides an opportunity to reduce the risk of cervical cancer, a second leading... -
- CITED
-
- Close
- SHARE
-
- Close
- Novel immunotherapy in metastatic renal cell carcinoma
-
Cho YH, Kim MS, Chung HS, Hwang EC
- KMID: 2410287
- Investig Clin Urol.
- 2017 Jul;58(4):220-227.
- doi: 10.4111/icu.2017.58.4.220
Despite the rapid development of therapeutic modalities for metastatic renal cell carcinoma (mRCC) over the past decade to include a number of targeted antiangiogenic therapies and traditional immunotherapy, such as... -
- CITED
-
- Close
- SHARE
-
- Close
- Cancer Immunotherapy: The Dawn of the Renaissance after the Medieval Dark Ages
-
Lee DH
- KMID: 2269238
- Korean J Med.
- 2014 Sep;87(3):284-295.
- doi: 10.3904/kjm.2014.87.3.284
Cancer immunotherapy has come a long way since William Coley observed that a mixture of killed bacteria, or Coley's toxin, induced tumor regression. However, enthusiasm for cancer immunotherapy has changed... -
- CITED
-
- Close
- SHARE
-
- Close
- Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles
-
Cho JH
- KMID: 2400624
- Immune Netw.
- 2017 Dec;17(6):378-391.
- doi: 10.4110/in.2017.17.6.378
Lung cancer is one of the leading causes of death worldwide. There are 2 major subtypes of lung cancer, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Studies show... -
- CITED
-
- Close
- SHARE
-
- Close
- Cancer Vaccines Targeting HER2/neu for Early Breast Cancer
-
Ryu WS, Son GS
- KMID: 2286553
- J Breast Cancer.
- 2010 Mar;13(1):5-13.
- doi: 10.4048/jbc.2010.13.1.5
Recent studies of immune responses to pathogens have identified pathogen-associated molecular patterns recognized by the innate immune system through specialized receptors called toll-like receptors (TLRs). Signaling through these receptors initiates... -
- CITED
-
- Close
- SHARE
-
- Close
- MUC1 from the Mucin Family as Potential Tools in Breast Cancer Immunotherapy
-
Park HK, Seov UH
- KMID: 2242001
- J Breast Cancer.
- 2009 Sep;12(3):125-133.
- doi: 10.4048/jbc.2009.12.3.125
Many breast cancer patients develop minimal residual disease that becomes resistance to treatments, and finally are faced with relapse and progression of disease. Currently, immunotherapy has become a potential therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Characterization of Anti-anti-idiotypic Antibodies (Ab3) Induced by Immunization of Anti-idiotypic Antibodies (Ab2) Mimicking Disialoganglioside GD2
-
Park YS
- KMID: 2150577
- Immune Netw.
- 2003 Jun;3(2):118-125.
- doi: 10.4110/in.2003.3.2.118
BACKGROUND: Disialoganglioside GD2 is a tumor-associated antigen that is overexpressed on tumor cells of neuroectodermal origin, such as melanoma and neuroblastoma. Anti-idiotypic antibodies that mimic GD2 may induce more effective... -
- CITED
-
- Close
- SHARE
-
- Close
- The Establishment of Dendritic Cell-Tumor Fusion Vaccines for Hormone Refractory Prostate Cancer Cell
-
Kim TB, Park HK, Chang JH, Choi IH, Kim KH, Yoon SJ, Lee MS, Jung H, Kim CS
- KMID: 2314814
- Korean J Urol.
- 2010 Feb;51(2):139-144.
PURPOSE: Dendritic cell (DC)-based tumor vaccine is an attractive modality for the treatment of hormone-refractory prostate cancer (HRPC) because it has some efficacy and few side effects in patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Monocyte Selection Method by Immunomagnetic Adsorption or Adherence for the Generation of Dendritic cells
-
Cheong KA, Choi OM, Choi SE, Lee H, Lee YJ
- KMID: 2300098
- Korean J Blood Transfus.
- 2004 Dec;15(2):213-219.
BACKGROUND: Dendritic cells (DCs) are the most potent stimulators of immune response including antitumor response. DCs are currently being pursued clinically in the development of cancer vaccines; therefore there are... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Dendritic Cells Matured Early with OK-432 (Picibanil(R)), Prostaglandin E2, and Interferon-alpha as a Vaccine for a Hormone Refractory Prostate Cancer Cell Line
-
Yoo C, Do HA, Jeong IG, Park H, Hwang JJ, Hong JH, Cho JS, Choo MS, Ahn H, Kim CS
- KMID: 1785906
- J Korean Med Sci.
- 2010 Sep;25(9):1284-1290.
- doi: 10.3346/jkms.2010.25.9.1284
Dendritic cells (DCs) are potent antigen-presenting cells. OK432 (Picibanil(R)) was introduced as a potent stimulator of DC maturation in combination with prostaglandin-E2 and interferon-alpha. We compared the efficacy of a... -
- CITED
-
- Close
- SHARE
-
- Close
- Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist
-
Pham TN, Hong CY, Min JJ, Rhee JH, Nguyen TA, Park BC, Yang DH, Park YK, Kim HR, Chung IJ, Kim HJ, Lee JJ
- KMID: 1078356
- Exp Mol Med.
- 2010 Jun;42(6):407-419.
- doi: 10.3858/emm.2010.42.6.042
Dendritic cells (DCs) play a role in natural killer (NK) cell activation, while NK cells are also able to activate and mature DCs. Toll-like receptors (TLRs) on the surface of... -
- CITED
-
- Close
- SHARE
-
- Close
- Glioma Stem Cell-Targeted Dendritic Cells as a Tumor Vaccine Against Malignant Glioma
-
Ji B, Chen Q, Liu B, Wu L, Tian D, Guo Z, Yi W
- KMID: 1776923
- Yonsei Med J.
- 2013 Jan;54(1):92-100.
- doi: 10.3349/ymj.2013.54.1.92
PURPOSE: Cancer stem cells have recently been thought to be closely related to tumor development and reoccurrence. It may be a promising way to cure malignant glioma by using glioma... -
- CITED
-
- Close
- SHARE
-
- Close
- Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination
-
Kim A, Noh YW, Kim KD, Jang YS, Choe YK, Lim JS
- KMID: 1123764
- Exp Mol Med.
- 2004 Oct;36(5):428-443.
Immunization with dendritic cells (DCs) pulsed with tumor antigen can activate tumor-specific cytotoxic T lymphocytes (CTL), which is responsible for tumor protection and regression. In this study, we examined whether... -
- CITED
-
- Close
- SHARE
-
- Close
- Biologic Therapy for Brain Cancers - Based on Cellular and Immunobiology
-
Okada H
- KMID: 1726149
- Yonsei Med J.
- 2004 Jun;45(Suppl):S68-S70.
- doi: 10.3349/ymj.2004.45.Suppl.68
The overall goal of our research projects is to develop effective immunotherapeutic regimens, particularly combining vaccine and gene therapy/ cell therapy strategies. For the development of clinically effective immunotherapy for... -
- CITED
-
- Close
- SHARE
-
- Close
- Antitumor immunity induced by tumor cells engineered to express a membrane-bound form of IL-2
-
Chang MR, Lee WH, Choi JW, Park SO, Paik SG, Kim YS
- KMID: 1056237
- Exp Mol Med.
- 2005 Jun;37(3):240-249.
Transduction of cytokine gene into tumor cells is a promising method of tumor therapy, but the value is limited by accompanying side effects. To focus antitumor immune response to tumor... -
- CITED
-
- Close
- SHARE
-
- Close
